Biotech Blueprint
Subscribe
Sign in
Home
Notes
This Week in Biotech
Deep Dives
Consulting
Archive
About
Latest
Top
Discussions
FDA Approves Moderna's mRNA Flu Vaccine, Takeda's Orzeyful, and Replimune's Tudriqev – This Week in Biotech #112
Three first-in-class approvals in seven days, Lilly's $23B quarter crushes Novo again, and a rumored $400B AstraZeneca-Bristol Myers merger knocks 9…
Aug 7
•
Katerina Roznik
4
July 2026
argenx's $2.2B Immunology Buy, J&J's In Vivo CAR-T Bet, and the FDA's Adcomm Revival – This Week in Biotech #111
argenx pays 86% premium for Forte's CD122 antibody, J&J commits $785M on in vivo CAR-T, and FDA panels turn on Capricor and Replimune (7/24-7/30, 2026).
Jul 31
•
Katerina Roznik
13
2
Retatrutide Underdelivers, Novo Sues Lilly, and GSK Wins a Fast Lung Cancer Approval – This Week in Biotech #110
Lilly's triple agonist misses on cardiovascular outcomes, Novo Nordisk takes Lilly to court over "deceptively false" ads, and Trump threatens 200…
Jul 24
•
Katerina Roznik
12
Merck's Oral PCSK9 Cholesterol Pill, Lilly's $2.8B Psychedelics Buy, and Makary's Regulatory Ghost – This Week in Biotech #109
Lipfendra becomes the first oral drug to match injectable cholesterol lowering, Lilly enters psychedelics with an $2.8B AtaiBeckley acquisition, and the…
Jul 17
•
Katerina Roznik
20
2
4
AstraZeneca's Amyloid Miss, Vertex's $10B Crinetics Buy, and Kidney Disease's Two-Drug Race – This Week in Biotech #108
Eplontersen fails in a market its competitors already own, Vertex makes its biggest deal ever to diversify beyond cystic fibrosis, and Vera Therapeutics…
Jul 10
•
Katerina Roznik
9
Happy 4th of July – This Week in Biotech #107
Roche beats two KRAS drugs at once, Anthropic starts making its own drugs, and biotech's XBI hits a five year high (June 26-July 2, 2026).
Jul 3
•
Katerina Roznik
11
1
June 2026
Washington Tries to Outcompete China, Lilly’s $1.9B Abbisko Bet, and Pfizer’s $43B Seagen Question – This Week in Biotech #106
HHS unveils a clinical trial reform blueprint as Lilly doubles down on Chinese discovery, Pfizer's lung cancer ADC fails, and US health spending hits…
Jun 26
•
Katerina Roznik
7
uniQure Wins a Surprise FDA Path in Huntington's, Moderna's mRNA Flu Vote, and a Record IPO Run – This Week in Biotech #105
The FDA reverses course on two products it had previously blocked, Lilly closes its fifteenth deal of 2026, and Kardigan pops 38% on debut to extend the…
Jun 19
•
Katerina Roznik
9
AstraZeneca Crashes the Obesity Party, Takeda Topples Sotyktu, and a Record Biotech IPO – This Week in Biotech #104
Elecoglipron makes obesity a four-player race, zasocitinib beats Bristol Myers Squibb head-to-head, and Parabilis prices the biggest venture-backed…
Jun 12
•
Katerina Roznik
11
1
1
China's First ASCO Plenary, a Standing Ovation for Daraxonrasib, and Washington's Counter-Move – This Week in Biotech #103
Akeso's ivonescimab beats a PD-1 inhibitor head-to-head in lung cancer, Revolution Medicines doubles survival in pancreatic cancer, and a House bill…
Jun 5
•
Katerina Roznik
6
May 2026
GSK Functionally Cures Hepatitis B, Lilly's $3.8B Vaccine Pivot, and Base Editing Holds for 18 Months – This Week in Biotech #102
A landmark antisense win in 254 million patients, Lilly's tenth deal of 2026 redraws its franchise map, and Verve's base editor holds for 18 months (May…
May 29
•
Katerina Roznik
11
28% Weight Loss: Lilly's Retatrutide Just Redefined the Obesity Market – This Week in Biotech #101
Plus the covert campaign that took out Makary, and a 65% lung cancer trial win that could reshape Keytruda's future (May 15-21, 2026).
May 22
•
Katerina Roznik
9
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
